Management of the axilla in early breast cancer: Is it time to change tack?

Australian and New Zealand Journal of Surgery

Volumn 70, Issue 4, 2000, Pages 288-296

  Crowe, Philip ^a,b,c   Temple, Walley ^a,b  

^a TOM BAKER CANCER CENTRE   (Canada)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Axillary dissection; Breast cancer; Sentinel lymph node biopsy

Indexed keywords

AXILLARY LYMPH NODE; BREAST CANCER; CANCER CONTROL; CANCER STAGING; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; PATIENT SELECTION; REVIEW; SURGICAL APPROACH;

AXILLA; BIOPSY; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES;

EID: 0034030949     PISSN: 00048682     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1622.2000.01801.x     Document Type: Review

References (110)

1. 1. Halsted WS. The results of operations for cure of cancer of the breast. Ann. Surg. 1907; 46: 1-9.
2. 2. Anonymous. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. N. Engl. J. Med. 1995; 333: 1444-55.
3. 3. Cady B, Stone MD, Schuler JG, Thakur R, Wanner MA, Lavin PT. The new era in breast cancer. Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. Arch. Surg. 1996; 131: 301-8.
4. 4. Moore MP, Kinne DW. Is axillary lymph node dissection necessary in the routine management of breast cancer? Yes. Important Adv. Oncol. 1996; 245-50.
5. 5. Donegan WL. Tumor-related prognostic factors for breast cancer. CA Cancer J. Clin. 1997; 47: 28-51.
6. 6. Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT. The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res. Treat. 1994; 32: 281-90.
7. 7. Clark GM, McGuire WL. New biologic prognostic factors in breast cancer. Oncology 1989; 3: 49-54.
8. 8. Ravdin PML, Vendely T, Clark GM. Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J. Natl Cancer Inst. 1994; 86: 1771-5.
9. 9. Kissin MW, Thompson EM, Price AB, Slavin G, Kark AE. The inadequacy of axillary sampling in breast cancer. Lancet 1982; 1: 1210-12.
10. 10. Graversen HP, Blichert-Toft M, Andersen JA, Zedeler K. Breast cancer: Risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur. J. Surg. Oncol. 1988; 14: 407-12.
11. 11. Moore MP, Kinne DW. Axillary lymphadenectomy: A diagnostic and therapeutic procedure. J. Surg. Oncol. 1997; 66: 2-6.
12. 12. Forrest A, Everington D, McDonald C, Steele RJC, Chetty U, Stewart H. The Edinburgh randomized trial of axillary sampling or clearance after mastectomy. Br. J. Surg. 1995; 82: 1504-8.
13. 13. Rageth JC, Wyss P, Unger C, Haller U. Axillary lymphadenectomy: Just how radical should it be? Surg. Oncol. 1996; 5: 37-41.
14. 14. Rosen PP, Lesser ML, Kinne DW, Beattie EJ. Discontinuous or 'skip' metastases in breast carcinoma. Analysis of 1228 axillary dissections. Ann. Surg. 1983; 197: 276-83.
15. 15. Markandoo P, Smith P, Chaudary MA, Fentiman IS. Preservation of pectoralis minor in axillary clearance for breast cancer. Br. J. Surg. 1998; 85: 1547-8.
16. 16. Moffat FLJ, Senofsky GM, Davis K, Clark KC, Robinson DS, Ketcham AS. Axillary node dissection for early breast cancer: Some is good, but all is better. J. Surg. Oncol. 1992; 51: 8-13.
17. 17. Kissin MW, Querci DR, Easton D, Westbury G. Risk of lymphoedema following the treatment of breast cancer. Br. J. Surg. 1986; 73: 580-4.
18. 18. Sosa JA, Diener-West M, Gusev Y et al. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. Ann. Surg. Oncol. 1998; 5: 140-9.
19. 19. Diab SG, Hilsenbeck SG, de Moor C et al. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J. Clin. Oncol. 1998; 16: 1655-60.
20. 20. Ragaz J, Jackson SM, Le N et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N. Engl. J. Med. 1997; 337: 956-62.
21. 21. Cabanes PA, Salmon RJ, Vilcoq JR et al. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. The Breast Carcinoma Collaborative Group of the Institut Curie. Lancet 1992; 339: 1245-8.
22. 22. Overgaard M, Hansen PS, Overgaard J et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N. Engl. J. Med. 1997; 337: 949-55.
23. 23. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival: A Baysian meta-analysis. Ann. Surg. Oncol. 1999; 6: 109-16.
24. 24. Morrow M. A survival benefit from axillary dissection: Was Halsted right? Ann. Surg. Oncol. 1999; 6: 17-18.
25. 25. Anonymous. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992; 339: 1-15.
26. 26. Morrow M. Axillary dissection: When and how radical? Semin. Surg. Oncol. 1996; 12: 321-7.
27. 27. Delaney G, Ung O, Cahill S, Bilous M, Boyages J. Ductal carcinoma in situ. Part 2: Treatment. Aust. N.Z. J. Surg. 1997; 67: 157-65.
28. 28. Simpson T, Thirlby RC, Dail D. Surgical management of ductal carcinoma in situ of the breast. Arch. Surg. 1992; 127: 468-72.
29. 29. Silver SA, Tavassoli FA. Mammary ductal carcinoma in situ with microinvasion. Cancer 1998; 82: 2382-90.
30. 30. Weiss MC, Fowble BL, Solin LJ, Yeh IT, Schultz DJ. Outcome of conservative therapy for invasive breast cancer by histologic subtype. Int. J. Radiat. Oncol. Biol. Phys. 1992; 23: 941-7.
31. 31. McDivitt RW, Boyce W, Gersell D. Tubular carcinoma of the breast: Clinical and pathological observations concerning 135 cases. Am. J. Surg. Pathol. 1982; 6: 401-11.
32. 32. Margolis DS, McMillen MA, Hashmi H, Wasson DW, MacArthur JD. Aggressive axillary evaluation and adjuvant therapy for nonpalpable carcinoma of the breast. Am. J. Surg. 1992; 174: 109-13.
33. 33. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181-7.
34. 34. Holland PA, Walls J, Boggis CR, Knox F, Baildam AD, Bundred NJ. A comparison of axillary node status between cancers detected at the prevalence and first incidence breast screening rounds. Br. J. Cancer 1996; 74: 1643-6.
35. 35. Kitchen PR, Cawson JN, Winch KL, Henderson MA. Characteristics and treatment of breast cancers 10 mm or less detected by a mammographic screening programme. Aust. N.Z. J. Surg. 1998; 68: 45-9.
36. 36. Giuliano AE, Barth AM, Spivack B, Beitsch PD, Evans SW. Incidence and predictors of axillary metastasis in T1 carcinoma of the breast. J. Am. Coll. Surg. 1996; 183: 185-9.
37. 37. White RE, Vezeridis MP, Konstadoulakis M, Cole BF, Wanebo HJ, Bland KI. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: Influence of axillary dissection for treatment of T1a and T1b lesions. J. Am. Coll. Surg. 1996; 183: 575-82.
38. 38. Chadha M, Axelrod D. Is axillary dissection always indicated in invasive breast cancer? Oncology 1997; 11: 1463-8, 1473.
39. 39. Halverson KJ, Taylor ME, Perez CA et al. Management of the axilla in patients with breast cancers one centimeter or smaller. Am. J. Clin. Oncol. 1994; 17: 461-6.
40. 40. Cowan WK, Kelly P, Sawan A et al. The pathological and biological nature of screen-detected breast carcinomas: A morphological and immunohistochemical study. J. Pathol. 1997; 182: 29-35.
41. 41. Velanovich V, Szymanski W. Lymph node metastasis in breast cancer: Common prognostic markers lack predictive value. Ann. Surg. Oncol. 1998; 5: 613-19.
42. 42. Fisher B, Redmond C, Fisher ER et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N. Engl. J. Med. 1985; 312: 674-81.
43. 43. Sun A, Liu FF, Pintilie M, Rawlings G. Outcome in breast cancer managed without an initial axillary lymph node dissection. Radiother. Oncol. 1998; 48: 191-6.
44. 44. Martelli G, DePalo G, Rossi N et al. Long-term follow-up of elderly patients with operable breast cancer treated with surgery without axillary dissection plus adjuvant tamoxifen. Br. J. Cancer 1995; 72: 1251-5.
45. 45. al-Hilaly M, Willsher PC, Robertson JF, Blamey RW. Audit of a conservative management policy of the axilla in elderly patients with operable breast cancer. Eur. J. Surg. Oncol. 1997; 23: 339-40.
46. 46. Maunsell E, Brisson J, Deschenes L. Arm problems and psychological distress after surgery for breast cancer. Can. J. Surg. 1993; 36: 315-20.
47. 47. Burak WEJ, Goodman PS, Young DC, Farrar WB. Seroma formation following axillary dissection for breast cancer: Risk factors and lack of influence of bovine thrombin. J. Surg. Oncol. 1997; 64: 27-31.
48. 48. Simon MS, Cody RL. Cellulitis after axillary lymph node dissection for carcinoma of the breast. Am. J. Med. 1992; 93: 543-8.
49. 49. Paredes JP, Puente JL, Potel J. Variations in sensitivity after sectioning the intercostobrachial nerve. Am. J. Surgery 1990; 160: 525-8.
50. 50. Browse DJ, Goble D, Jones PA. Axillary node clearance: Who wants to immobilize the shoulder? Eur. J. Surg. Oncol. 1996; 22: 569-70.
51. 51. Hoe AL, Iven D, Royle GT, Taylor I. Incidence of arm swelling following axillary clearance for breast cancer. Br. J. Surg. 1992; 79: 261-2.
52. 52. Larson D, Weinstein M, Goldberg I et al. Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1986; 12: 1575-82.
53. 53. Mazeron JJ, Otmezguine Y, Huart J, Pierquin B. Conservative treatment of breast cancer: Results of management of axillary lymph node area in 3353 patients. Lancet 1985; 1: 1387-90.
54. 54. Pierce SM, Recht A, Lingos TI. Long-term complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast disease. Int. J. Radiat. Oncol. Biol. Phys. 1992; 23: 915-23.
55. 55. Powell S, Cooke J, Parsons C. Radiation induced brachial plexus injury: Follow up of two different treatment schedules. Radiother. Oncol. 1990; 18: 213-20.
56. 56. Reintgen D, Cruse W, Wells K. The next revolution in general surgery. Ann. Surg. Oncol. 1999; 6: 125-6.
57. 57. Morton DL, Wen DR, Wong JH et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg. 1992; 127: 392-9.
58. 58. Alex JC, Krag DN. Gamma-probe guided localization of lymph nodes. Surg. Oncol. 1993; 2: 137-43.
59. 59. Reintgen D. More rational and conservative surgical strategies for malignant melanoma using lymphatic mapping and sentinel node biopsy techniques. Curr. Opin. Oncol. 1996; 8: 152-8.
60. 60. Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann. Surg. 1997; 226: 271-6.
61. 61. Turner-Warick RT. The lymphatics of the breast. Br. J. Surg. 1959; 46: 574-82.
62. 62. Uren RF, Howman-Giles RB, Thompson JF et al. Mammary lymphoscintigraphy in breast cancer. J. Nucl. Med. 1995; 36: 1775-80.
63. 63. Veronesi U, Cascinelli N, Bufalino R et al. Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients. Ann. Surg. 1983; 198: 681-4.
64. 64. Lacour J, Le M, Caceres E, Koszarowski T, Veronesi U, Hill C. Radical mastectomy versus radical mastectomy plus internal mammary dissection. Ten year results of an international cooperative trial in breast cancer. Cancer 1983; 51: 1941-3.
65. 65. Veronesi U, Valagussa P. Inefficacy of internal mammary nodes dissection in breast cancer surgery. Cancer 1981; 47: 170-5.
66. 66. Morrow M, Foster Jr RS. Staging of breast cancer: A new rationale for internal mammary node biopsy. Arch. Surg. 1981; 116: 748-51.
67. 67. Dowlatshahi K, Fan M, Snider HC, Habib FA. Lymph node micrometastases from breast carcinoma: Reviewing the dilemma. Cancer 1997; 80: 1188-97.
68. 68. Cody HS, Urban JA. Internal mammary node status: A major prognosticator in axillary node-negative breast cancer. Ann. Surg. Oncol. 1995; 2: 32-7.
69. 69. O'Hea BJ, Hill AD, El-Shirbiny AM et al. Sentinel lymph node biopsy in breast cancer: Initial experience at Memorial Sloan-Kettering Cancer Center. J. Am. Coll. Surg. 1998; 186: 423-7.
70. 70. Krag D, Weaver D, Ashikaga T et al. The sentinel node in breast cancer: A multicenter validation study. N. Engl. J. Med. 1998; 339: 941-6.
71. 71. Egan RL, McSweeney MB. Intramammary lymph nodes. Cancer 1983; 51: 1838-42.
72. 72. Lindfors KK, Kopans DB, Googe PB, McCarthy KA, Koerner FC, Meyer JE. Breast cancer metastasis to intramammary lymph nodes. AJR 1986; 146: 133-6.
73. 73. Thompson JF, Niewind P, Uren RF, Bosch CM, Howman-Giles R, Vrouenraets BC. Single-dose isotope injection for both preoperative lymphoscintigraphy and intraoperative sentinel lymph node identification in melanoma patients. Melanoma Res. 1997; 7: 500-6.
74. 74. Krag D, Harlow S, Weaver D, Ashikaga T. Technique of sentinel node resection in melanoma and breast cancer: Probe-guided surgery and lymphatic mapping. Eur. J. Surg. Oncol. 1998; 24: 89-93.
75. 75. Gulec SA, Moffat FL, Carroll RG et al. Sentinel lymph node localization in early breast cancer. J. Nucl. Med. 1998; 39: 1388-93.
76. 76. Offodile R, Hoh C, Barsky SH et al. Minimally invasive breast carcinoma staging using lymphatic mapping with radiolabeled dextran. Cancer 1998; 82: 1704-8.
77. 77. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg. Oncol. 1993; 2: 335-9.
78. 78. Veronesi U, Paganelli G, Galimberti V et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancer 1997; 349: 1864-7.
79. 79. Borgstein PJ, Pijpers R, van Comans EFD, Boom RP, Meijer S. Sentinel lymph node biopsy in breast cancer: Guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J. Am. Coll. Surg. 1998; 186: 275-83.
80. 80. Giuliano AE. Intradermal blue dye to identify sentinel lymph node in breast cancer. Lancet 1997; 350: 958.
81. 81. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann. Surg. 1994; 220: 391-8.
82. 82. Barnwell JM, Arredondo MA, Kollmorgen D et al. Sentinel node biopsy in breast cancer. Ann. Surg. Oncol. 1998; 5: 126-30.
83. 83. Borgstein PJ, Meijer S, Pijpers R. Intradermal blue dye to identify sentinel lymph-node in breast cancer. Lancet 1997; 349: 1668-9.
84. 84. Albertini JJ, Lyman GH, Cox C et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276: 1818-22.
85. 85. Miner TJ, Shriver CD, Jaques DP, Maniscalco-Theberge ME, Krag DN. Ultrasonographically guided injection improves localization of the radiolabeled sentinel lymph node in breast cancer. Ann. Surg. Oncol. 1998; 5: 315-21.
86. 86. Uren RF, Thompson JF, Howman-Giles R. Sentinel-lymph node biopsy in breast cancer. Lancet 1998; 352: 1472-3.
87. 87. Pijpers R, Meijer S, Hoekstra OS et al. Impact of lymphoscintigraphy on sentinel node identification with technetium-99m-colloidal albumin in breast cancer. J. Nucl. Med. 1997; 38: 366-8.
88. 88. Roumen RM, Valkenburg JG, Geuskens LM. Lymphoscintigraphy and feasibility of sentinel node biopsy in 83 patients with primary breast cancer. Eur. J. Surg. Oncol. 1997; 23: 495-502.
89. 89. Linehan DC, Hill AD, Akhurst T et al. Intradermal radiocolloid and intraparenchymal blue dye injection optimize sentinel node identification in breast cancer patients. Ann. Surg. Oncol. 1999; 6: 450-4.
90. 90. Brady MS, Coit DG. Sentinel lymph node evaluation in melanoma. Arch. Dermatol. 1997; 133: 1014-20.
91. 91. Flett MM, Going JJ, Stanton PD, Cooke TG. Sentinel node localization in patients with breast cancer. Br. J. Surg. 1998; 85: 991-3.
92. 92. Guenther JM, Krishnamoorthy M, Tan LR. Sentinel lymphadenectomy for breast cancer in a community managed care setting. Cancer J. Sci. Am. 1997; 3: 336-40.
93. 93. Galimberti V, Zurrida S, Zucali P, Veronesi U. Can sentinel node biopsy avoid axillary node dissection in clinically node-negative breast cancer patients? Breast J. 1998; 7: 8-10.
94. 94. Hill AD, Tran KN, Akhurst T et al. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann. Surg. 1999; 229: 528-35.
95. 95. Haigh PI, Hansen NM, Qi K, Giuliano AE. Method of biopsy and excision volume do not affect success rate of subsequent sentinal lymph node dissection in breast cancer. Cancer Symposium of the Society of Surgical Oncology, Orlando, FL., 1999.
96. 96. Cox CE, Bass S, Boulware D, Ku N, Berman C, Reintgen DS. Implementation of a new surgical technology: Outcome measures for lymphatic mapping of breast carcinoma. Cancer Symposium of the Society of Surgical Oncology, Orlando, FL., 1999.
97. 97. Ludwig Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International (Ludwig) Breast Cancer Study Group. Lancet 1990; 335: 1565-8.
98. 98. Hainsworth PJ, Tjandra JJ, Stillwell RG et al. Detection and significance of occult metastases in node-negative breast cancer. Br. J. Surg. 1993; 80: 459-63.
99. 99. Meyer JS. Sentinel lymph node biopsy: Strategies for pathologic examination of the specimen. J. Surg. Oncol. 1998; 69: 212-18.
100. 100. Turner RR, Giuliano AE. Intraoperative pathologic examination of the sentinel lymph node. Ann. Surg. Oncol. 1999; 5: 670-2.
101. 101. Schreiber RHPS, Ku N, Reintgen D et al. Microstaging of breast cancer patients using cytokeratin staining of the sentinel lymph node. Ann. Surg. Oncol. 1999; 69: 95-101.
102. 102. Clare SE, Sener SF, Wilkens W, Goldschmidt R, Merkel D, Winchester DJ. Prognostic significance of occult lymph node metastases in node-negative breast cancer. Ann. Surg. Oncol. 1997; 4: 447-51.
103. 103. De Mascarell I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: Reevaluation with longer follow-up. Br. J. Cancer 1992; 66: 523-7.
104. 104. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J. Clin. Oncol. 1997; 15: 2345-50.
105. 105. Min CJ, Tafra L, Verbanac KM. Identification of superior markers for polymerase chain reaction detection of breast cancer metastases in sentinel lymph nodes. Cancer Res. 1998; 58: 4581-4.
106. 106. Turner RR, Ollila DW, Stern S, Giuliano AE. Optimal histopathologic examination of the sentinel lymph node for breast carcinoma staging. Am. J. Surg. Pathol. 1999; 23: 263-7.
107. 107. Jannick I, Fan M, Nagy S, Rayudu G, Dowlatshahi K. Serial sectioning of sentinel nodes in patients with breast cancer: A pilot study. Ann. Surg. Oncol. 1998; 5: 310-14.
108. 108. McNeil C. Sentinel node biopsy: Studies should bring needed data. J. Natl Cancer Inst. 1998; 90: 728-9.
109. 109. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13.
110. 110. Petitti DB. Hormone replacement therapy and heart disease prevention: Experimentation trumps observation. JAMA 1998; 280: 650-2.